FTL Announces Investigation of Molina Healthcare, Inc.
2005年7月30日 - 5:18AM
PRニュース・ワイアー (英語)
FTL Announces Investigation of Molina Healthcare, Inc. WASHINGTON,
July 29 /PRNewswire/ -- The law firm of Finkelstein, Thompson &
Loughran announces that a lawsuit seeking class action status has
been filed in the United States District Court for the Central
District of California on behalf of all persons who purchased the
securities of Molina Healthcare, Inc. (NASDAQ:MOH) ("Molina
Healthcare" or the "Company") between November 3, 2004 and July 20,
2005, inclusive (the "Class Period"). Finkelstein, Thompson &
Loughran is investigating similar claims at this time and welcomes
inquiries from potential class members concerning their rights and
interests in this matter. The lawsuit alleges that Molina
Healthcare violated federal securities laws by issuing false or
misleading public statements. Specifically, the complaint alleges
that Molina Healthcare: (1) expanded rapidly through acquisitions
and underestimated the financial impact of assimilating its
acquisitions, while failing to make favorable contracts with
various providers; (2) the acquisitions and unfavorable contracts
resulted in significant increases in healthcare costs; (3) failed
to account for and efficiently counteract a higher than expected
number of catastrophic cases, increased maternity costs and an
increase in outpatient services; (4) and that as a result of the
foregoing, the Company's forecasts were lacking in any reasonable
basis when made. On July 20, 2005, the Company announced a revision
of its full year earnings forecast, dropping its previous estimate
of $2.40 to $2.45 per share, downward to between $0.73 to $0.80 per
share. Further, Molina Healthcare announced that it expects a
second quarter loss of between $0.15 to $0.20 per share. In
reaction to this news, the Company's share price dropped from
$46.00 on July 20, 2005, to $26.00 on July 21, 2005 -- constituting
a decline of nearly 44% in a single day. If you are a member of the
class, you may, no later than September 26, 2005, request that the
Court appoint you as a lead plaintiff. A lead plaintiff is a class
member appointed by the Court to direct the litigation on behalf of
the class. Although a class member need not be appointed as a lead
plaintiff to receive a proportionate share of any proceeds of the
litigation, lead plaintiffs make important decisions that could
affect the prosecution of the class claims, including decisions
concerning settlement. The securities laws create a rebuttable
presumption that the plaintiff with the largest financial interest
in the litigation is the most adequate to serve as a lead
plaintiff. With offices in Washington, DC and San Francisco, CA,
Finkelstein, Thompson & Loughran has spent almost three decades
delivering outstanding representation to institutional and
individual clients in connection with securities and other
finance-related litigation, and has been appointed as lead or
co-lead counsel in dozens of shareholder class actions. Indeed, in
the past ten years, the firm has served in leadership roles in
cases that have recovered over $1 billion for investors and
consumers. If you have any questions concerning this press release
or your rights or interests, please contact Finkelstein, Thompson
& Loughran's Washington, DC office, toll-free, at
1-877-337-1050, by email at , or by submitting an inquiry form
located at http://www.ftllaw.com/news/releases/050729Molina.html.
DATASOURCE: Finkelstein, Thompson & Loughran CONTACT: Donald J.
Enright, Esq. of Finkelstein, Thompson & Loughran,
+1-202-337-8000 Web site: http://www.ftllaw.com/
Copyright